April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Feb 21, 2024, 18:13

Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“Tremelimumab plus durvalumab (STRIDE) in HCC:
HIMALAYA update

  • 1171 patients, first line, STRIDE or Durva or sorafenib
  • STRIDE versus sorafenib, OS: HR 0.78 (0.67-0.92
  • durvalumab versus sorafenib, OS: HR 0.86 (0.74-1.01)
  • long-term OS benefit of STRIDE versus sorafenib
  • Durvalumab maintained OS noninferiority to sorafenib.”

Proceed to the article.
Source: Erman Akkus/X